ChemicalBook >> CAS DataBase List >>3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide

CAS No.
1009298-59-2
Chemical Name:
3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide
Synonyms
CS-486;AZD2014;AZD2014, >=98%;AZD 2014; AZD-2014;AZD2014(Vistusertib);Vistusertib (AZD2014);Osimertinib Impurity 4;AZD2014;AZD 2014; AZD-2014;Vistusertib, 98%, a novel mTOR inhibitor;3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide
CBNumber:
CB02604239
Molecular Formula:
C25H30N6O3
Molecular Weight:
462.54
MDL Number:
MFCD22628784
MOL File:
1009298-59-2.mol
MSDS File:
SDS
Last updated:2023-06-08 09:02:20

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide Properties

Melting point 233-237oC
Density 1.231
storage temp. -20°C Freezer
solubility Chloroform (Slightly), Methanol (Slightly)
pka 14.45±0.46(Predicted)
form Solid
color Light Yellow
FDA UNII 0BSC3P4H5X

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
HS Code  29339900
NFPA 704
0
2 0

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide price More Price(28)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 17378 AZD 2014 ≥98% 1009298-59-2 1mg $32 2024-03-01 Buy
Cayman Chemical 17378 AZD 2014 ≥98% 1009298-59-2 5mg $93 2024-03-01 Buy
Cayman Chemical 17378 AZD 2014 ≥98% 1009298-59-2 10mg $146 2024-03-01 Buy
Cayman Chemical 17378 AZD 2014 ≥98% 1009298-59-2 25mg $305 2024-03-01 Buy
TRC A808115 AZD2014 1009298-59-2 200mg $890 2021-12-16 Buy
Product number Packaging Price Buy
17378 1mg $32 Buy
17378 5mg $93 Buy
17378 10mg $146 Buy
17378 25mg $305 Buy
A808115 200mg $890 Buy

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide Chemical Properties,Uses,Production

Uses

AZD2014 is a dual mTORC1 and mTORC2 inhibitor. Studies show that AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines.

Biological Activity

azd2014 is a novel, potent and highly selective dual inhibitor of the mammalian rapamycin (mtorc1 and mtorc2) with an ic50 value of 2.8 nm. it is an oral inhibitor and possesses potential antineoplastic activity.azd2014 enhanced susceptibility of glioblastoma stem-like cells (gscs) to irradiation both in vitro and under orthotopic in vivo conditions. kahn j et al pretreated cd133+ and cd15+ gsc cells with azd2014 (2 μm) for 1 hour, followed by irradiation. the effect was then measured by clonogenic survival analysis [2]. using in vitro screening, they demonstrated that the combination of ibrutinib, an inhibitor of the tyrosine kinase btk, and azd2014 could dramatically induce apoptosis in abc-subtype dlbcl cell lines. thereby, the combination of azd2014 with a btk inhibitor is a promising therapeutic method to cure patients with abc-type dlbcl [3]. in hepatocellular carcinoma cells, azd2014 gave rise to a more complete inhibition of mtorc1 than rapamycin, while the inhibition of mtorc2 prevented the feedback activation of akt signaling. therefore, azd2014 was identified to be more efficacious in the induction of apoptosis, autophagy, and cell cycle arrest, resulting in a significant proliferation suppression of the cells, in contrast with rapamycin [4].in a recent human pharmacokinetic and pharmacodynamic study, a dose of 50mg bd(twice a day)azd2014 was recommended to achieve pharmacologically relevant plasma concentrations [5].

target

mTOR

References

optimization of potent and selective dual mtorc1 and mtorc2 inhibitors: the discovery of azd8055 and azd2014. bioorg med chem lett. 2013 mar 1;23(5):1212-6. the mtorc1/mtorc2 inhibitor azd2014 enhances the radiosensitivity of glioblastoma stem-like cells. neuro oncol. 2014 jan;16(1):29-37. synergistic induction of apoptosis by combination of btk and dual mtorc1/2 inhibitors in diffuse large b cell lymphoma. oncotarget. 2014 jul 15;5(13):4990-5001.dramatic antitumor effects of the dual mtorc1 and mtorc2 inhibitor azd2014 in hepatocellular carcinoma. am j cancer res. 2014 dec 15;5(1):125-39. ecollection 2015.first-in-human pharmacokinetic and pharmacodynamic study of the dual m-torc 1/2 inhibitor, azd2014. clin cancer res. 2015 mar 24. pii: clincanres.2422.2014.

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 154)Suppliers
Supplier Tel Email Country ProdList Advantage
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29914 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 967 58
Hubei Jusheng Technology Co.,Ltd.
18871490254 linda@hubeijusheng.com CHINA 28180 58
Standardpharm Co. Ltd.
86-714-3992388 overseasales1@yongstandards.com United States 14336 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873 sales@chemdad.com China 39916 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 19892 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226 sales@hzclap.com CHINA 6313 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 29220 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10523 58

View Lastest Price from 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide pictures 2019-07-06 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide
1009298-59-2
US $2.00 / kg 1kg 99% 100kg Career Henan Chemical Co

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide Spectrum

3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide AZD2014 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide AZD2014 AZD2014 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide 3-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-N-methylbenzamide AZD2014, >=98% AZD2014(Vistusertib) AZD2014;AZD 2014; AZD-2014 Vistusertib, 98%, a novel mTOR inhibitor Vistusertib (AZD2014) CS-486 AZD 2014; AZD-2014 Osimertinib Impurity 4 Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl- 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide USP/EP/BP inhibit,Vistusertib,Apoptosis,Mammalian target of Rapamycin,AZD 2014,mTOR,Autophagy,Inhibitor,AZD-2014 1009298-59-2 Inhibitors Akt mTOR PI3K PI3K/Akt/mTOR